

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**SUPPLEMENTAL ANNOUNCEMENT
DIVERSITY OF BOARD MEMBERS UNDER RULE 13.92 OF
THE LISTING RULES**

Reference is made to the announcement of Wai Chun Bio-Technology Limited (the “**Company**”) dated 1 April 2024 (the “**Announcement**”) in relation to the change of independent non-executive director (“**INED**”) of the Company. Unless otherwise defined, capitalised terms herein shall have the same meanings as referred to in the Announcement.

DIVERSITY OF BOARD MEMBERS UNDER RULE 13.92 OF THE LISTING RULES

Pursuant to Rule 13.92 of the Listing Rules, the Stock Exchange will not consider diversity to be achieved for a single gender board. Following the resignation of Ms. Hong as an INED with effect from 1 April 2024 as announced by the Company, the Board does not have a Director of a different gender, and hence the Company has not been in compliance with the requirement under Rule 13.92 of the Listing Rules.

The Board will use its best endeavour to identify a suitable female candidate that meet relevant requirements. In making the appointment of a Director, a number of factors including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills and knowledge will be taken into account with an aim to make the Board more diverse, and the decision will be made based on merits in accordance with the nomination policy of the Company.

It is expected that the Board will appoint a suitable female candidate as Director within three months from the date of the resignation of Ms. Hong in order to ensure compliance by the Company with the requirement under Rule 13.92 of the Listing Rules. Further announcement will be made by the Company as and when appropriate.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Executive Director

Hong Kong, 11 April 2024

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer) and two independent non-executive Directors, namely Mr. Wan Bo and Mr. HE Tao.